Overall, the data suggest that ganaxolone is efficacious in reducing seizure frequency in a variety of disorders, including CDKL5, Lennox-Gastaut syndrome, and PCDH19 patients. This evidence concerns the gene PCDH19 and Lennox-Gastaut syndrome.